Healthcare Review: OraSure Technologies , Amarin Corporation, Keryx Biopharmaceuticals, Gentium Are Big Movers Print E-mail
By Staff and Wire Reports   
Wednesday, 10 October 2012 13:17
U.S. stocks on Wednesday extended losses after aluminum producer Alcoa Inc. cut its outlook for global demand for the metal and Chevron Corp. warned of lower earnings. In recent months, warnings from a broad swath of American corporations have directed expectations lower, prompting analysts to predict the first profit decline in three years, so the third-quarter expectations bar is already low.

Following are the notable movers at mid day on Wednesday.

OraSure Technologies, Inc.(NASDAQ:OSUR)
shares climbed 4.60% to $10.68 in the morning hour. The company’s OraQuick, which allows people to screen for HIV at home, won’t help slow transmissions of the virus, a public health specialist and an infectious disease doctor said in an editorial.

Additionally, Cowen initiated coverage on shares of OSUR in a research report sent to investors last week. The firm issued a neutral rating on the stock.

Amarin Corporation plc (ADR)(NASDAQ:AMRN)
shares dropped 7.42% to $10.98 after Amarin revealed that the FDA still has not made a decision regarding Vascepa's New Chemical Entity (NCE) status. After communications with the FDA, Amarin says the governing body will likely not include Vascepa's exclusivity status in the September issue of the Orange Book, due out in mid-October.

Additionally, Amarin‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a note issued to investors yesterday.

Keryx Biopharmaceuticals(NASDAQ:KERX)
stock increased 6.18% to $2.92. Keryx stock had its price target boosted by Ladenburg Thalmann from $3.00 to $5.00 in a research report released today. Ladenburg Thalmann currently has a buy rating on the stock.

Separately, analysts at Oppenheimer reiterated an outperform rating on shares of Keryx in a research note to investors on September 5.

Gentium S.p.A. (ADR)(NASDAQ:GENT)
stock dropped 5.31% to $9.99 after the company announced that it has received a second List of Outstanding Issues ("LoOIs") from the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") in connection with the Company's Marketing Authorization Application ("MAA") for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy.

The company, last week, announced the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle East and North Africa (MENA). Under the terms of the agreement, which is valid for 10 years, Biologix will be responsible for managing named-patient requests and obtaining price and reimbursement approvals in the MENA region.

NxStage Medical, Inc.(NASDAQ:NXTM)
shares climbed 3.70% to $13.15 in the early hour. The company announced plans to release its financial results for the third quarter ended September 30, 2012 on Thursday, November 8, 2012 before the opening of the financial markets.

Additionally, Wells Fargo & Co. upgraded shares of NXTM from an underperform rating to a market perform rating in a report issued today.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus